A team of scientists has uncovered a previously overlooked set of immune cells that appear to protect the gut from the kind of runaway inflammation seen in Crohn's disease and ulcerative colitis.
The discovery, reported in the journal Nature by researchers at the US National Institutes of Health (NIH), could pave the way for smarter, more targeted treatments for people living with inflammatory bowel disease (IBD).
For years, the focus on gut immunity has been on a type of T cell that acts as a peacekeeper, helping prevent the immune system from attacking the intestines, reports biome sci.
But the new work puts another group firmly in the frame: a specialised subset of cells that act like bouncers in the gut, stepping in to shut down inflammatory troublemakers before they wreck the place.
However, when these cells are faulty, they don't make it to the gut lining. Without that patrol, harmful inflammation can spiral, and in severe cases, can spark early-onset IBD.
How the cells fight IBD
The newly spotlighted cells appear to have a very specific brief. They track into the thin layer of tissue that lines the bowel and stand guard. When immune cells called macrophages become overactivated by injury or disease, they move in and switch them off decisively.
They do so through well-known immune system kill switches that keep inflammation from blasting through the intestinal wall, which is exactly what causes the pain, bleeding and urgent dashes to the loo many people with IBD endure during a flare.
Crucially, the whole system hinges on a receptor that acts like a satnav for these cells. It tells them where to go – into the gut lining, not elsewhere.
If that guidance system is broken, the protective cells don't turn up where they're needed, the inflammatory cells pile up, and tissue damage follows.
Different IBD treatments
IBD can knock people out of work, disrupt school and family life, and mean repeated hospital trips. There are millions of people worldwide living with Crohn's and colitis.
Today's drugs often work by dampening down large parts of the immune system. While that can help, it also raises the risk of infections and other side effects, and for some patients, the relief doesn't last.
The new study points towards a different strategy: rather than blunting immunity across the board, restore the body's own circuit for settling gut inflammation. Therapies that strengthen or top up the discovered cells could, in time, calm flares with fewer trade-offs.
One of the study's senior authors, Dr Chuan Wu, said the aim now is to explore treatments that will be a more precise fix than blanket suppression.
Another lead researcher, Dr Michael Lenardo, called the findings a fresh route to targeted therapies for a condition that can be sometimes-debilitating, while stressing this is an early step.
